The number of patients (%) or median [minimum–maximum] | |
---|---|
Male | 17 (47.2) |
Primary disease | |
diabetic nephropathy | 9 (25.0) |
IgA nephropathy | 7 (19.4) |
polycystic kidney | 3 (8.3) |
chronic glomerulonephritis | 2 (5.5) |
focal glomerulosclerosis | 2 (5.5) |
Alport syndrome | 1 (2.7) |
cystinosis | 1 (2.7) |
mesangial proliferative glomerulonephritis | 1 (2.7) |
unknown | 10 (26.0) |
Agea | 47 [28–66] |
Body weight (kg)a | 55.5 [34.8–105.9] |
Serum albumin (g/dL)a | 4.0 [2.9–5.1] |
Serum creatinine (mg/dL)a | 1.1 [0.5–2.9] |
Estimated creatinine clearance (mL/min)a | 57.5 [24.9–113.8] |
Total bilirubin (mg/dL)a | 0.6 [0.2–1.6] |
Alanine aminotransferase (IU/mL)a | 12 [4–117] |
Aspartate aminotransferase (IU/mL)a | 17 [6–109] |
Mycophenolate mofetil dose at one time (mg) | |
Postoperative day < 31 | 1000 [500–1000] |
Postoperative day ≥ 31 | 500 [250–1000] |
Actual AUC0-12 of mycophenolic acid (μg▪h/mL) | |
Postoperative day < 31 | 52.7 [23.6–89.2] |
Postoperative day ≥ 31 | 43.7 [21.5–87.6] |
Oral clearance of mycophenolate acid | |
Postoperative day < 31 | 18.0 [10.2–32.7] |
Postoperative day ≥ 31 | 12.5 [6.4–34.1] |
Postoperative day | |
Postoperative day < 31 | 14 [7–21] |
Postoperative day ≥ 31 | 359 [34–2832] |
Concomitant druga ,b | |
Postoperative day < 31 | |
Proton pump inhibitor | 34 (34.0) |
Proton pump inhibitor + Quinolone | 4 (4.0) |
Postoperative day ≥ 31 | |
Quinolone | 22 (22.0) |
Proton pump inhibitor | 16 (16.0) |
Proton pump inhibitor + Quinolone | 17 (17.0) |
Proton pump inhibitor + Valganciclovir | 2 (2.0) |